Holen Sie sich die Stockscreener-App
1.68
2.33%
-0.04
Handel nachbörslich:
1.71
0.03
+1.79%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LXRX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$1.72
Offen:
$1.72
24-Stunden-Volumen:
2.69M
Relative Volume:
0.97
Marktkapitalisierung:
$711.78M
Einnahmen:
$49.80M
Nettoeinkommen (Verlust:
$-50.34M
KGV:
-12.10
EPS:
-0.1388
Netto-Cashflow:
$-67.85M
1W Leistung:
+7.69%
1M Leistung:
+12.00%
6M Leistung:
+25.37%
1J Leistung:
+370.46%
1-Tages-Spanne:
$1.65
$1.77
1-Wochen-Bereich:
$1.515
$1.77
52-Wochen-Spanne:
$0.32
$1.83
Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile
Firmenname
Lexicon Pharmaceuticals Inc
Sektor
Branche
Telefon
(281) 863-3000
Adresse
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Compare LXRX vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
1.68 | 728.73M | 49.80M | -50.34M | -67.85M | -0.1388 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-05 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-06-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-30 | Eingeleitet | Leerink Partners | Outperform |
| 2023-03-07 | Eingeleitet | Jefferies | Hold |
| 2022-08-12 | Eingeleitet | Piper Sandler | Overweight |
| 2021-01-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-01-29 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-12-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-11-18 | Hochstufung | Gabelli & Co | Hold → Buy |
| 2019-12-11 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2019-11-08 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-09-11 | Hochstufung | Gabelli & Co | Hold → Buy |
| 2019-07-29 | Herabstufung | Stifel | Buy → Hold |
| 2019-03-25 | Hochstufung | Gabelli & Co | Sell → Hold |
| 2018-07-31 | Bestätigt | Stifel | Buy |
| 2018-02-23 | Herabstufung | Needham | Buy → Hold |
| 2018-02-14 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2017-03-01 | Bestätigt | H.C. Wainwright | Buy |
| 2017-03-01 | Bestätigt | Wedbush | Outperform |
| 2016-10-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-08-05 | Bestätigt | Wedbush | Outperform |
| 2016-08-02 | Eingeleitet | Citigroup | Buy |
| 2016-03-02 | Bestätigt | Wedbush | Outperform |
| 2015-11-09 | Bestätigt | Wedbush | Outperform |
| 2015-09-28 | Hochstufung | Gabelli & Co | Sell → Hold |
| 2015-09-18 | Herabstufung | Gabelli & Co | Hold → Sell |
| 2015-08-10 | Herabstufung | JP Morgan | Overweight → Neutral |
Alle ansehen
Lexicon Pharmaceuticals Inc Aktie (LXRX) Neueste Nachrichten
LXRX Stock Up as NVO Initiates Phase I Study of Partnered Obesity Drug - Yahoo Finance
Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo - Bitget
Lexicon brings ACC data showing heart benefits across BMI groups - Stock Titan
Lexicon Pharmaceuticals (LXRX) Receives Reiterated Buy Rating at $6.00 | LXRX Stock News - GuruFocus
Lexicon Pharmaceuticals' (LXRX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Lexicon Pharmaceuticals And Novo Nordisk Announce Initiation Of Phase 1 Study With Oral Obesity Drug Candidate LX9851 - TradingView
Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851 - Yahoo Finance
HC Wainwright remains a buy on Lexicon Pharmaceuticals (LXRX) - MSN
Published on: 2026-03-22 17:56:17 - baoquankhu1.vn
LXRX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
H.C. Wainwright Remains a Buy on Lexicon Pharmaceuticals (LXRX) - Insider Monkey
Lexicon Pharmaceuticals advances chronic pain treatment options with focus on non opioid innovation - Traders Union
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2025 Earnings Call Transcript - MSN
Lexicon Pharma spikes after insider buy - MSN
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price Crosses Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Growth Value: How does Lexicon Pharmaceuticals Inc compare to its peers2026 EndofMonth & Low Drawdown Investment Ideas - baoquankhu1.vn
Dip Buying: How much upside does Lexicon Pharmaceuticals Inc have2026 PreEarnings & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
HC Wainwright raises its price target on Lexicon Pharmaceuticals, Inc. (LXRX) to $6 from $4 and maintains a buy rating - MSN
Lexicon Pharmaceuticals, Inc.Common Stock (NQ: LXRX - The Chronicle-Journal
Lexicon Pharmaceuticals (LXRX) 2025 10-K: pipeline updates, collaborations - Stock Titan
Lexicon Pharmaceuticals (NASDAQ: LXRX) asks holders to double shares, renew equity plans - Stock Titan
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Rapid Micro Biosystems (RPID), Lexicon Pharmaceuticals (LXRX) and Whitehawk Therapeutics (WHWK) - The Globe and Mail
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q4 2025 earnings call transcript - MSN
H.C. Wainwright reiterates Buy on Lexicon Pharmaceuticals stock By Investing.com - Investing.com Canada
H.C. Wainwright Raises its Price Target on Lexicon Pharmaceuticals, Inc. (LXRX) to $6 from $4 and Maintains a Buy Rating - Insider Monkey
Lexicon Pharmaceuticals at Leerink Conference: Strategic Pipeline Focus By Investing.com - Investing.com Canada
LXRX: Late-stage trials and regulatory milestones drive pipeline progress and strategic partnerships - TradingView
Lexicon Pharmaceuticals (LXRX) to Present Key Findings on Sotagl - GuruFocus
Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes - The Manila Times
Diabetes drug sotagliflozin cut low-sugar events, across kidney stages - Stock Titan
Citigroup Raises Price Target for Lexicon Pharmaceuticals (LXRX) - GuruFocus
Citigroup Forecasts Strong Price Appreciation for Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock - MarketBeat
Lexicon Pharmaceuticals Signals Leaner Path to Key Milestones - TipRanks
What is HC Wainwright's Estimate for LXRX Q1 Earnings? - MarketBeat
Quarterly Risk: How does Lexicon Pharmaceuticals Inc compare to its peersQuarterly Earnings Summary & Daily Entry Point Trade Alerts - baoquankhu1.vn
Lexicon Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:LXRX) 2026-03-08 - Seeking Alpha
Volume Summary: Does Lexicon Pharmaceuticals Inc meet Warren Buffetts criteria2025 Retail Activity & Weekly High Return Forecasts - baoquankhu1.vn
Structure Therapeutics Stock Surges 200% This Past Year as One Fund Cuts Stake by $15.5 Million - AOL.com
LXRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Lexicon Pharmaceuticals prices $94.6M share offering - MSN
Lexicon Pharmaceuticals Q4 2025 earnings preview - MSN
Lexicon Pharmaceuticals 2025 Financial Report: Q4 Loss Narrows, Beats EstimatesNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Up 5.8% Following Earnings Beat - MarketBeat
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q4 2025 Earnings Call Transcript - Insider Monkey
FY2027 Earnings Forecast for LXRX Issued By HC Wainwright - MarketBeat
Lexicon outlines 2026 milestones as SONATA-HCM enrollment surpasses 50% and cash position is strengthened - MSN
HIMs 22% Collapse Looks Like A ‘Buy The Dip’ Moment - AOL.com
Lexicon Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
H.C. Wainwright Maintains Buy on LXRX Lexicon Pharmaceuticals Mar 2026 - Meyka
Lexicon Pharmaceuticals 2025 10-K: $49.8M Revenue, $0.14 EPS Loss - TradingView
Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates - Bitget
Finanzdaten der Lexicon Pharmaceuticals Inc-Aktie (LXRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):